Last year, LGM Pharma expanded its Analytical Testing Services (ATS) to meet growing demand for endotoxin and rapid sterility testing capabilities. Adding these tests under the same roof has accelerated product release while ensuring product quality and satisfying regulatory requirements, critical new capabilities for developers of sterile and injectable pharmaceuticals, including ophthalmic solutions.
The cornerstone of this progress has been platform upgrades that have enabled two advanced microbiology capabilities: endotoxin testing and rapid sterility testing. These enhancements strengthen LGM’s comprehensive suite of microbiological assays, which also include bioburden testing, Antimicrobial Effectiveness Testing (AET) and Burkholderia cepacia complex (BCC) testing. Read More >
